PSPN.SW (PSPN.SW)

$7.2B
Market Cap
17.6
P/E Ratio
0.53
Beta
2.54%
Dividend Yield
Piotroski 7/9Altman Z 1.8 Gray ZoneROIC−WACC -2.5%

Quantitative Summary

Deterministic

Strong operational fundamentals (Piotroski 7/9) with Altman Z of 1.8.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency for PSPN.SW presents a significant concern, as the return on invested capital of 4.5% falls short of the weighted average cost of capital by 2.5%, indicating value destruction from current operations despite an impressive Piotroski F-Score of 7/9 which suggests strong financial health and operational stability. This anomaly is further complicated by a massive net margin expansion to 114.4% paired with a gross margin of 94.2%; while these figures typically signal high-margin software or service models, they may reflect non-recurring gains or accounting adjustments rather than sustainable core profitability, especially given the negative revenue growth trajectory of -3.0%. The Altman Z-Score of 1.8 places the entity in a "gray zone" approaching distress territory, suggesting that while balance sheet leverage might be manageable, liquidity risks warrant heightened scrutiny compared to peers with scores above 2.5.

Valuation metrics currently reflect market skepticism regarding future growth prospects despite the elevated profitability ratios. With a price-to-earnings multiple of 17.6x, the stock trades at a premium relative to its own historical norms if earnings are depressed by recent revenue contraction, yet it remains difficult to assess against sector averages without specific benchmark data provided in this dataset. A discounted cash flow analysis anchors fair value at $22, implying that current market pricing may be disconnected from intrinsic value assumptions dependent on the assumed terminal growth rates and discount inputs used in the model. The divergence between the high margin structure and declining top-line revenue suggests the market is likely pricing in a correction of these anomalies rather than immediate recovery, creating a valuation gap that depends entirely on whether management can reverse the -3.0% revenue trend to justify the premium multiple.

The convergence of negative free cash flow generation implied by an ROIC-WACC spread below zero and a Z-Score hovering near distress creates a distinct risk/reward asymmetry where downside protection appears limited despite strong balance sheet indicators from the Piotroski score. Investors must weigh whether the 17.6x multiple compensates for the potential earnings quality issues hinted at by the extreme margin figures or if it represents an overvaluation of a company struggling with top-line momentum. Without additional data on insider trading activity or specific Fama-French factor exposures, the primary driver of future performance appears to be the ability to stabilize revenue growth while maintaining capital efficiency in an environment where current returns fail to cover the cost of equity and debt financing.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →6%7%9%
2%$24$8$0
3%$49$22$0
4%$97$46$3

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=7.0%, terminal growth 3%. Fair value $22 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

7/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
1.8
Altman Z-Score
Grey Zone — between 1.8 and 3.0 thresholds. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

94.2%
Gross Margin
114.4%
Net Margin
4.5%
ROIC
7.0%
WACC
ROIC − WACC Spread: -2.5%— Negative spread.
-3.0%
Revenue Growth (YoY)
+8.9%
Earnings Growth (YoY)
160.1M
Free Cash Flow
112%
FCF Payout Ratio

⚠️ Dividend consumes >80% of FCF — sustainability risk.

Balance Sheet Health

0.80x
Debt / Equity
0.30x
Current Ratio
15.4x
Interest Coverage
5.1x
Net Debt / EBITDA
1.60%
FCF Yield
540.1M
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $1.26
Act: $1.09
-13.4%
Q3
✗ Miss
Est: $1.28
Act: $1.24
-2.7%
Q2
✓ Beat
Est: $1.27
Act: $1.29
+2.0%
Q1
✓ Beat
Est: $1.29
Act: $1.29
+0.1%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

30.2
Forward P/E
PEG Ratio
1.28
Price/Book
76711
Avg Volume
$168.40
52W High
$128.80
52W Low
52W Range Position

PSPN.SW Capital Efficiency

How efficiently does PSPN.SW convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$160M
EBITDA
$540M
FCF Conversion
30%
Reinvestment Rate
70%
30% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
4.5%
ROIC − WACC Spread
-2.5%

PSPN.SW converts 30% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 70% reinvestment rate signals aggressive capacity expansion. However, the ROIC-WACC spread is negative (-2.5%), suggesting reinvested capital is destroying shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare PSPN.SW to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.